Prakash Gowd joined TIAP in January 2024 as Vice President and took on the role of Interim President & CEO in April 2026.

An accomplished healthcare and life sciences executive, Prakash brings over 25 years of diverse experience across biopharma, capital markets, and entrepreneurship. His track record spans private and public companies, startups and large corporations, and different business models, healthcare verticals and emerging sectors.  As a leader and strategist, he has held responsibility for people, P&Ls, financing, licensing, M&A, and go-public leadership.

Prior to TIAP, Prakash was Chief Operating Officer and Head of Corporate Development at a mental health and psychedelic medicine company, where he led the development of a clinic network, took the company public, managed U.S. operations, and oversaw acquisitions and the eventual sale of the business.  Previously, as co-founder of a health technology company focused on individualized treatment strategies in a newly regulated market, he helped build the team, launch the product, and guide the company through to acquisition.

Prakash is also an experienced capital markets professional, having served in senior biotech equity research and investment banking roles at CIBC World Markets, National Bank Financial, and Canaccord Capital.  The foundation of his career was built over many years in commercial operations and new product development in the pharmaceutical industry.

Prakash serves on the boards of BioSyent (RX-TSXV), Appili Therapeutics (APLI-TSX) and HDAX Therapeutics (private), and has previously served as Director at FendX Technologies and Isotechnika Pharma (now Aurinia Pharmaceuticals). He holds an MBA from McGill University, degrees in Pharmacy and Zoology from the University of British Columbia, and is a Chartered Director.